TG Therapeutics Inc. (TGTX) Trading Up 4.5%
Shares of TG Therapeutics Inc. (NASDAQ:TGTX) were up 4.5% during trading on Tuesday . The company traded as high as $6.56 and last traded at $6.46, with a volume of 172,037 shares changing hands. The stock had previously closed at $6.18.
A number of analysts have recently commented on TGTX shares. S&P Equity Research cut their price objective on TG Therapeutics from $7.15 to $6.40 in a research report on Wednesday, August 24th. Roth Capital restated a “buy” rating and issued a $33.00 price objective on shares of TG Therapeutics in a research report on Wednesday, August 10th. Zacks Investment Research cut TG Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 14th. SunTrust Banks Inc. started coverage on TG Therapeutics in a research report on Friday, May 27th. They issued a “buy” rating and a $18.00 price objective for the company. Finally, Brean Capital restated a “buy” rating on shares of TG Therapeutics in a research report on Tuesday, May 31st. One analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. TG Therapeutics has a consensus rating of “Buy” and a consensus target price of $20.71.
The firm has a 50-day moving average price of $6.00 and a 200-day moving average price of $7.62. The company’s market cap is $345.80 million.
TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by $0.04. On average, equities research analysts forecast that TG Therapeutics Inc. will post ($1.23) EPS for the current fiscal year.
TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. The Company is developing over two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.